NGeneBio Co

NGeneBio Co Equity Ratio

The Equity Ratio of NGeneBio Co (354200.KQ) as of Nov 17, 2026 is 31.75 %. In the previous year, Equity Ratio was 51.52 % — a change of -38.38% (lower).

Equity Ratio

31.75 %

YoY

-38.38%

Last updated:

Equity Ratio of NGeneBio Co is 2025 31.75 % . Equity Ratio of NGeneBio Co was 2024 51.52 % . It decreases by -38.38% lower compared to the previous year.

The NGeneBio Co Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
-24.98 KRW
Jan 1, 2019
26.66 KRW
Jan 1, 2020
83.92 KRW
Jan 1, 2021
77.50 KRW
Jan 1, 2022
45.04 KRW
Jan 1, 2023
38.54 KRW
Jan 1, 2024
51.52 KRW
Jan 1, 2025
31.75 KRW
The NGeneBio Co Equity Ratio history
YEAREquity RatioYoY
31.75 %-38.38%
51.52 %+33.70%
38.54 %-14.44%
45.04 %-41.88%
77.50 %-7.64%
83.92 %+214.77%
26.66 %-206.74%
-24.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

Equity Ratio of NGeneBio Co is 31.75 % in 2025.

Equity Ratio of NGeneBio Co changed from 51.52 % to 31.75 %, representing a -38.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's NGeneBio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — NGeneBio Co

All Key Metrics — NGeneBio Co